Abstract:Ilaria Ottonelli, 1, &ast Elisa Adani, 2, &ast Andrea Bighinati, 2 Sabrina Cuoghi, 1 Giovanni Tosi, 1, 3 Maria Angela Vandelli, 1 Barbara Ruozi, 1 Valeria Marigo, 2, 3 Jason Thomas Duskey 1 1 Nanotech Lab, Te.Far.T.I., Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy; 2 Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy; 3 Center for Neuroscience and Neurotechnology, Modena, Italy &astThese authors contributed equally to this work Correspondence: Jason Thomas Duskey, Nanotech Lab, Te.Far.T.I., Department of Life Sciences, University of Modena and Reggio Emilia, Via Giuseppe Campi 103, Modena, MO, Italy, 41125, Tel +390592058573, Email Valeria Marigo, Department of Life Sciences, University of Modena and Reggio Emilia, Via Giuseppe Campi 287, Modena, MO, 41125, Italy, Tel +390592055392, Email Purpose: In recent years, microfluidic technologies have become mainstream in producing gene therapy nanomedicines (NMeds) following the Covid-19 vaccine; however, extensive optimizations are needed for each NMed type and genetic material. This article strives to improve LNPs for pDNA loading, protection, and delivery, while minimizing toxicity. Methods: The microfluidic technique was optimized to form cationic or neutral LNPs to load pDNA. Classical "post-formulation" DNA addition vs "pre" addition in the aqueous phase were compared. All formulations were characterized (size, homogeneity, zeta potential, morphology, weight yield, and stability), then tested for loading efficiency, nuclease protection, toxicity, and cell uptake. Results: Optimized LNPs formulated with DPPC: Chol:DOTAP 1:1:0.1 molar ratio and 10 μg of DOPE-Rhod, had a size of 160 nm and good homogeneity. The chemico-physical characteristics of cationic LNPs worsened when adding 15 μg/mL of pDNA with the "post" method, while maintaining their characteristics up to 100 μg/mL of pDNA with the "pre" addition remaining stable for 30 days. Interestingly, neutral LNPs formulated with the same method loaded up to 50% of the DNA. Both particles could protect the DNA from nucleases even after one month of storage, and low cell toxicity was found up to 40 μg/mL LNPs. Cell uptake occurred within 2 hours for both formulations with the DNA intact in the cytoplasm, outside of the lysosomes. Conclusion: In this study, the upcoming microfluidic technique was applied to two strategies to generate pDNA-LNPs. Cationic LNPs could load 10x the amount of DNA as the classical approach, while neutral LNPs, which also loaded and protected DNA, showed lower toxicity and good DNA protection. This is a big step forward at minimizing doses and toxicity of LNP-based gene therapy. Keywords: gene therapy, lipid nanoparticles, microfluidics, lipoplexes, DNA delivery Nanomedicines (NMeds) have been designed to improve half-life, stability, lower necessary doses, offer targeted delivery, and importantly, protect the pharmaceutical molecule. 1–6 This has led to NMeds becoming a major point of interest in the research for new pharmaceutical options in the treatment of almost every major, orphan, and hard to treat disease. 7–13 The advantages of the use of NMeds are even more evident with the advancement of gene therapeutics where the genetic material must be well protected from the immune system, delivered to the site of interest with high specificity, enter into the cell, and arrive at the point of interest (nucleus or cytoplasm) in a sufficient amount for a therapeutic effect. 14–17 In fact, when discussing DNA delivery, and/or its co-delivery with other molecules such as siRNA, great strides have already, and still are, being made demonstrating these capabilities in a variety of NMed systems ranging from dendrimers, 18–22 inorganic, 23–25 polymeric, 26–31 and lipidic 32–36 nanoparticles which were able to protect, target, and effectively transfect genes in in vitro studies. Cationic charges have been primarily used to stabilize the DNA through charge interaction in order to protect the plasmid DNA being delivered, even though the charge interaction with cell surface proteins was correlated to cell toxicity. 37–40 Recently, research has drifted away from large pDNA towards the use of siRNA and mRNA for their small size, high expression, and ability to knock down or lead to protein expression respectively without having to enter the nucleus; however, they also suffer from easy degradation during formulation and after administration, making their use difficult. While a drawback for p -Abstract Truncated-

Ionizable Lipid Nanoparticle-Mediated Delivery of Plasmid DNA in Cardiomyocytes

Reiterated Targeting Peptides on the Nanoparticle Surface Significantly Promote Targeted Vascular Endothelial Growth Factor Gene Delivery to Stem Cells.

Fusogenic Coiled-Coil Peptides Enhance Lipid Nanoparticle-Mediated Mrna Delivery Upon Intramyocardial Administration.

Cardiac delivery of modified mRNA using lipid nanoparticles: Cellular targets and biodistribution after intramyocardial administration

Strategies for Improved pDNA Loading and Protection Using Cationic and Neutral LNPs with Industrial Scalability Potential Using Microfluidic Technology

Lipid Nanoparticles: A Novel Gene Delivery Technique for Clinical Application

"All in one" lipid-polymer nanodelivery system for gene therapy of ischemic diseases

Lipid Nanoparticles for Nucleic Acid Delivery to Endothelial Cells

The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery

Delivery of Plasmid DNA by Ionizable Lipid Nanoparticles to Induce CAR Expression in T Cells

Ultrasound- and Liposome Microbubble-Mediated Targeted Gene Transfer to Cardiomyocytes in Vivo Accompanied by Polyethylenimine.

Nanotechnology-based non-viral vectors for gene delivery in cardiovascular diseases

Engineered nanoparticles promote cardiac tropism of AAV vectors

Controllable Large-Scale Transfection of Primary Mammalian Cardiomyocytes on a Nanochannel Array Platform

Conventional and microfluidic methods: Design and optimization of lipid-polymeric hybrid nanoparticles for gene therapy

Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: Advances in genome editing and CAR T cell therapy

In Vivo Introduction of mRNA Encapsulated in Lipid Nanoparticles to Brain Neuronal Cells and Astrocytes via Intracerebroventricular Administration

Non-Viral Gene Delivery Systems for Treatment of Myocardial Infarction: Targeting Strategies and Cardiac Cell Modulation

Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation

Branched‐Tail Lipid Nanoparticles for Intravenous mRNA Delivery to Lung Immune, Endothelial, and Alveolar Cells in Mice

Looking Back, Moving Forward: Lipid Nanoparticles as a Promising Frontier in Gene Delivery